What is the recommended management of Crohn’s disease strictures, including indications for endoscopic balloon dilation, medical therapy, and surgery?

Management of Crohn's Disease Strictures

The management of Crohn's strictures depends critically on distinguishing inflammatory from fibrotic components and anatomical characteristics: predominantly inflammatory strictures with active disease should receive optimized medical therapy (particularly anti-TNF biologics), while symptomatic fibrotic strictures require endoscopic balloon dilation for short (<4-5 cm) accessible lesions or surgical intervention for longer, complex, or refractory strictures. 1, 2

Initial Assessment and Characterization

Imaging Evaluation

• A stricture is definitively present when there is luminal narrowing with unequivocal upstream bowel dilation (>3 cm). 1
• Cross-sectional imaging with CT or MR enterography must document the number, location, and length of strictures to guide therapeutic decisions. 1
• Most Crohn's strictures contain both inflammatory and fibrotic components, making treatment selection complex. 1
• Degree of upstream dilation helps predict treatment response: moderate dilation (3-4 cm) responds better to anti-TNF therapy than massive dilation (>4 cm) or paradoxically no dilation. 1

Critical Imaging Features to Report

• Wall thickness: Mild (3-5 mm), Moderate (5-9 mm), Severe (≥10 mm) 1
• Mural enhancement patterns indicating active inflammation (stratified or transmural hyperenhancement) 1
• Presence of ulcerations (marker of severe inflammation requiring aggressive medical therapy) 1
• Associated complications: fistulas, abscesses, or mass-like features suggesting malignancy 1

Medical Therapy for Inflammatory Strictures

When to Use Medical Management

• Anti-TNF biologics represent the highest quality evidence for treating strictures with inflammatory components and should be optimized using a treat-to-target strategy. 3
• Medical therapy can alleviate inflammation and potentially avoid or delay surgery when significant inflammatory features are present on imaging. 1
• Biologics cannot reverse established fibrosis—this is a critical limitation that must guide expectations. 2

Predictors of Medical Therapy Success

• Shorter duration of obstructive symptoms with moderate (not massive) upstream dilation 1
• Imaging evidence of active inflammation (mural hyperenhancement, wall edema on T2-weighted MRI) 1
• Predominantly fibrotic strictures will fail medical therapy and require mechanical intervention. 1, 2

Endoscopic Balloon Dilation

Optimal Candidates for EBD

Balloon dilation is appropriate first-line therapy for ileocolonic anastomotic strictures <4 cm in length, without sharp angulation and with non-penetrating disease. 1

Technical Specifications

• Technical success rate is 89-92% for appropriate candidates. 2
• Endoscopically accessible ileal strictures are amenable to dilation, but have higher complication and recurrence rates compared to anastomotic strictures. 1
• Perforation risk is approximately 3%, requiring surgical backup availability. 2, 4
• Strictures <5 cm in length without adjacent fistulization are ideal candidates. 4

Contraindications to EBD

• Strictures >5 cm in length 4
• Presence of fistulae or abscesses 1
• Sharp angulation preventing safe balloon passage 1
• Significant prestenotic dilation suggesting high-grade obstruction 3

Expected Outcomes

• The majority of patients will require repeated dilations—this should be discussed upfront. 1
• EBD serves as a bridge therapy to defer surgery rather than definitive treatment in most cases. 4

Surgical Management

Immediate Surgical Referral (Emergency)

Immediate surgical consultation is mandatory for: 2

• Free perforation with peritonitis
• Hemodynamic instability
• Signs of bowel ischemia or strangulation
• Complete bowel obstruction with clinical deterioration after 24-48 hours of medical management

Elective Surgical Referral Criteria

Surgery is indicated for: 1, 2

• Symptomatic strictures that are medically-resistant despite optimized biologic therapy
• Predominantly fibrotic strictures (medical therapy ineffective)
• Symptomatic obstruction persisting despite 72 hours of conservative management—delaying beyond this increases morbidity and mortality 2

Surgical Options

Strictureplasty

Strictureplasty is preferred for: 1

• Multiple jejunoileal strictures
• Previous extensive small bowel resection or impending short gut syndrome
• Recurrent strictures requiring bowel length preservation

Contraindications to strictureplasty: 1

• Fistulae or fistula-associated abscesses
• Possible carcinoma (evaluate for nodularity, asymmetry, mesenteric extension)

Technical approach: 1

• Heineke-Mikulicz technique for strictures up to 10 cm
• Finney procedure for intermediate length (10-25 cm)
• Michelassi procedure (enteroenterostomy) for longer strictures

Active inflammation at the stricture site does not prevent successful strictureplasty. 1

Segmental Resection

• Preferred for localized ileocecal disease with fibrotic stricture 2
• Wide-lumen stapled side-to-side anastomosis technique recommended 2
• For multiple strictures close together in a bowel segment with adequate remaining healthy bowel, single resection is preferable to multiple strictureplasties. 1

Critical Pitfalls to Avoid

Delayed Recognition of Fibrotic Disease

• Continuing medical therapy for predominantly fibrotic strictures delays necessary intervention and risks complete obstruction or perforation. 2
• Cross-sectional imaging showing proximal dilation >4 cm with minimal inflammatory features should prompt early surgical discussion. 1

Underestimating Severity in Patients on Biologics

• Patients on biologics may have blunted inflammatory response—absence of fever or leukocytosis does not exclude ischemia or perforation. 2
• Maintain high clinical suspicion for complications despite reassuring laboratory values. 2

Inappropriate EBD Attempts

• EBD should only be attempted with surgical backup immediately available given 3% perforation risk. 2
• Do not attempt dilation of strictures with adjacent fistulas or abscesses. 1, 4

Failure to Document Stricture Characteristics

• Radiologists must report number, location, length, degree of upstream dilation, and inflammatory features to enable appropriate treatment selection. 1
• Inadequate imaging characterization leads to suboptimal therapeutic decisions. 1

Treatment Algorithm

1. Confirm stricture presence: Luminal narrowing with upstream dilation >3 cm on cross-sectional imaging 1

2. Characterize stricture: Length, location, inflammatory vs. fibrotic features, degree of upstream dilation 1

3. Assess for complications: Fistulas, abscesses, perforation, malignancy 1

4. Predominantly inflammatory stricture (<4 cm, moderate symptoms): Optimize anti-TNF biologic therapy with treat-to-target approach 1, 3

5. Short anastomotic or ileal stricture (<4-5 cm, symptomatic, no fistula): Endoscopic balloon dilation with surgical backup 1, 2

6. Fibrotic stricture, long stricture (>5 cm), or failed medical/endoscopic therapy: Surgical consultation for strictureplasty vs. resection 1, 2

7. Emergency features (perforation, ischemia, complete obstruction >48 hours): Immediate surgery 2